Article
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
Lung cancer (Amsterdam, Netherlands) - 1 May 2020
Eide Inger Johanne Zwicky, Helland Åslaug, Ekman Simon, Mellemgaard Anders, Hansen Karin Holmskov, Cicenas Saulius, Koivunen Jussi, Grønberg Bjørn Henning, Brustugun Odd Terje
Abstract excerpt
OBJECTIVES: In non-small cell lung cancer patients with acquired resistance to first- or second-generation EGFR-TKIs, osimertinib is approved in the presence of the T790 M resistance mutation. We assessed the efficacy of osimertinib in both T790M-positive and T790M-negative patients. MATERIALS AND METHODS: The TREM-study is an investigator-initiated, multi-centre, single-arm, phase 2 clinical trial conducted in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.